 AN EVALUATION OF THE OPTIMAL DOSE OF TOFACITINIB NEEDED TO ACHIEVE LOW DISEASE ACTIVITY LDA OR CLINICAL REMISSION IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS RA AS MEASURED FROM A CLINICAL AND STRUCTURAL PERSPECTIVE: 